Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Nexsen Limited ( (AU:NXN) ) has provided an announcement.
Nexsen Limited has announced that 20.2 million fully paid ordinary shares currently held in escrow will be released and made eligible for quotation on the ASX in February 2026, comprising 6 million shares held by key research partner RMIT University and 14.2 million shares held by various pre-IPO investors. The newly tradable securities, which rank equally with existing shares on issue, will modestly increase Nexsen’s free float and could enhance trading liquidity, while underscoring the long-term alignment of the company’s research partner and early backers with its strategy in the rapidly evolving point-of-care diagnostics market.
More about Nexsen Limited
Nexsen Limited is an Australian diagnostics company developing rapid point-of-care tests that deliver lab-grade results for conditions traditionally dependent on slower laboratory testing. Its lead product, the GBS Rapid Sensor, targets Group B Streptococcus in maternal health, and the company is also advancing rapid kidney function diagnostics for Acute Kidney Injury and Chronic Kidney Disease, conditions affecting hundreds of millions globally. With additional diagnostics in human health, ag-tech and biosecurity, Nexsen aims to position itself as a global leader in rapid point-of-care diagnostics to ease healthcare system pressures and improve patient outcomes.
Average Trading Volume: 341,421
Find detailed analytics on NXN stock on TipRanks’ Stock Analysis page.